JPWO2020223550A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223550A5 JPWO2020223550A5 JP2021564784A JP2021564784A JPWO2020223550A5 JP WO2020223550 A5 JPWO2020223550 A5 JP WO2020223550A5 JP 2021564784 A JP2021564784 A JP 2021564784A JP 2021564784 A JP2021564784 A JP 2021564784A JP WO2020223550 A5 JPWO2020223550 A5 JP WO2020223550A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cells
- cfp
- composition
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841183P | 2019-04-30 | 2019-04-30 | |
| US201962841190P | 2019-04-30 | 2019-04-30 | |
| US62/841,190 | 2019-04-30 | ||
| US62/841,183 | 2019-04-30 | ||
| US16/827,381 US11026973B2 (en) | 2019-04-30 | 2020-03-23 | Engineered phagocytic receptor compositions and methods of use thereof |
| US16/827,302 | 2020-03-23 | ||
| US16/827,381 | 2020-03-23 | ||
| US16/827,302 US11013764B2 (en) | 2019-04-30 | 2020-03-23 | Engineered phagocytic receptor compositions and methods of use thereof |
| PCT/US2020/030837 WO2020223550A1 (fr) | 2019-04-30 | 2020-04-30 | Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531325A JP2022531325A (ja) | 2022-07-06 |
| JPWO2020223550A5 true JPWO2020223550A5 (fr) | 2023-05-10 |
Family
ID=73029265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564784A Pending JP2022531325A (ja) | 2019-04-30 | 2020-04-30 | 操作されたキメラ融合タンパク質組成物およびそれらの使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3962497A4 (fr) |
| JP (1) | JP2022531325A (fr) |
| KR (1) | KR20220045930A (fr) |
| CN (1) | CN114072157A (fr) |
| AU (1) | AU2020266595A1 (fr) |
| BR (1) | BR112021021843A8 (fr) |
| CA (1) | CA3135531A1 (fr) |
| GB (2) | GB2600834A (fr) |
| IL (1) | IL287650A (fr) |
| MX (1) | MX2021013355A (fr) |
| SG (1) | SG11202111985XA (fr) |
| WO (1) | WO2020223550A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CA3073421A1 (fr) | 2017-09-26 | 2019-04-04 | Daniel Mark COREY | Molecules de recepteur d'engloutissement chimerique et methodes d'utilisation |
| AU2019205912A1 (en) | 2018-01-03 | 2020-07-16 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| GB2605276A (en) | 2019-09-03 | 2022-09-28 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
| GB2617474A (en) | 2020-11-04 | 2023-10-11 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
| KR20230138473A (ko) * | 2021-01-06 | 2023-10-05 | 팔레온 파마슈티칼스 인크. | 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법 |
| AU2022268146A1 (en) | 2021-04-28 | 2023-11-16 | Sanquin IP B.V. | Chimeric fc-alpha receptors and uses thereof |
| CN113214408B (zh) * | 2021-04-30 | 2022-12-27 | 清华大学深圳国际研究生院 | 一种嵌合抗原受体巨噬细胞及其制备方法和用途 |
| GB202108366D0 (en) * | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
| CN113817677B (zh) * | 2021-09-29 | 2023-08-18 | 四川大学 | 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途 |
| WO2023194607A1 (fr) * | 2022-04-07 | 2023-10-12 | Institut Curie | Cellules myéloïdes modifiées par un récepteur antigénique chimérique avec cd40 et leurs utilisations pour une thérapie anticancéreuse |
| WO2023194608A1 (fr) * | 2022-04-07 | 2023-10-12 | Institut Curie | Cellules myéloïdes modifiées par un récepteur antigénique chimérique et leurs utilisations pour une thérapie anticancéreuse |
| KR20230162310A (ko) * | 2022-05-20 | 2023-11-28 | 주식회사 카나프테라퓨틱스 | Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10590182B2 (en) * | 2015-02-24 | 2020-03-17 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| EP3286225B1 (fr) * | 2015-04-23 | 2020-07-01 | Baylor College of Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
| MX2018001182A (es) * | 2015-07-28 | 2018-04-20 | Univ Pennsylvania | Monocitos/macrofagos modificados que expresan receptores de antigeno quimerico y sus usos. |
| WO2017025944A2 (fr) * | 2015-08-13 | 2017-02-16 | Brigham Young University | Car macrophage (moto-car) en immunothérapie |
| US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
| JP7208010B2 (ja) * | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
| EP4089116A1 (fr) * | 2016-09-27 | 2022-11-16 | Cero Therapeutics, Inc. | Molécules de récepteurs d'engloutissement chimériques |
| WO2018073394A1 (fr) * | 2016-10-19 | 2018-04-26 | Cellectis | Récepteurs d'antigènes chimériques induisant la mort cellulaire |
| CN110461868A (zh) * | 2016-11-01 | 2019-11-15 | 根马布私人有限公司 | 多肽变体及其用途 |
| WO2018140831A2 (fr) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Conjugués ciblant les tumeurs et leurs méthodes d'utilisation |
| CN111479921A (zh) * | 2017-09-18 | 2020-07-31 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
-
2020
- 2020-04-30 SG SG11202111985XA patent/SG11202111985XA/en unknown
- 2020-04-30 JP JP2021564784A patent/JP2022531325A/ja active Pending
- 2020-04-30 CA CA3135531A patent/CA3135531A1/fr active Pending
- 2020-04-30 WO PCT/US2020/030837 patent/WO2020223550A1/fr unknown
- 2020-04-30 GB GB2115849.8A patent/GB2600834A/en active Pending
- 2020-04-30 GB GBGB2406391.9A patent/GB202406391D0/en active Pending
- 2020-04-30 KR KR1020217038628A patent/KR20220045930A/ko unknown
- 2020-04-30 BR BR112021021843A patent/BR112021021843A8/pt unknown
- 2020-04-30 AU AU2020266595A patent/AU2020266595A1/en active Pending
- 2020-04-30 CN CN202080048311.9A patent/CN114072157A/zh active Pending
- 2020-04-30 EP EP20798060.8A patent/EP3962497A4/fr active Pending
- 2020-04-30 MX MX2021013355A patent/MX2021013355A/es unknown
-
2021
- 2021-10-28 IL IL287650A patent/IL287650A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2600834A (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| CN112119097B (zh) | 自然杀伤细胞接合抗体融合构建体 | |
| JPWO2020223550A5 (fr) | ||
| Holder et al. | Engineering interferons and interleukins for cancer immunotherapy | |
| JP6557657B2 (ja) | 分子 | |
| EP4013792A1 (fr) | Molécules de liaison multimériques immunostimulatrices | |
| JP2021088601A (ja) | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 | |
| CN110382539B (zh) | 用于cd16a定向的nk细胞结合的串联双抗体 | |
| JP2022553464A (ja) | 多重特異性抗体とその製造方法および使用 | |
| JP2019500012A5 (fr) | ||
| JP2022549186A (ja) | 高い標的密度の細胞に対する選択性を向上させた多量体抗体 | |
| JP2022521937A (ja) | ＮＫｐ３０に結合する抗体分子およびその使用 | |
| US20220047677A1 (en) | Immune cell function | |
| US20230398216A1 (en) | Chimeric activation receptors | |
| US20210079111A1 (en) | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof | |
| GB2623191A (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| CA3212950A1 (fr) | Amelioration de la fonction de cellules immunitaires | |
| CN117836328A (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| CN117616050A (zh) | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 | |
| CA3173176A1 (fr) | Anticorps anti-tumeur associes a l'antigene et leurs utilisations | |
| CA3152272A1 (fr) | Systeme de recepteurs antigeniques chimeriques et leurs utilisations | |
| Teschner | Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy | |
| WO2024037626A1 (fr) | Anticorps bispécifique se liant à tnfr2 et à 4-1bb | |
| WO2022253248A1 (fr) | Variant d'anticorps anti-cd3, protéine de fusion et application | |
| WO2024114605A1 (fr) | Polypeptide de fusion et son utilisation |